These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27841047)

  • 1. Therapy with atorvastatin versus rosuvastatin reduces urinary podocytes, podocyte-associated molecules, and proximal tubule dysfunction biomarkers in patients with type 2 diabetes mellitus: a pilot study.
    Vlad A; Vlad M; Petrica L; Ursoniu S; Gadalean F; Popescu R; Vlad D; Dumitrascu V; Gluhovschi G; Gluhovschi C; Velciov S; Bob F; Matusz P; Secara A; Simulescu A; Jianu DC
    Ren Fail; 2017 Nov; 39(1):112-119. PubMed ID: 27841047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proximal tubule dysfunction is associated with podocyte damage biomarkers nephrin and vascular endothelial growth factor in type 2 diabetes mellitus patients: a cross-sectional study.
    Petrica L; Vlad A; Gluhovschi G; Gadalean F; Dumitrascu V; Gluhovschi C; Velciov S; Bob F; Vlad D; Popescu R; Milas O; Ursoniu S
    PLoS One; 2014; 9(11):e112538. PubMed ID: 25397960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Podocyturia parallels proximal tubule dysfunction in type 2 diabetes mellitus patients independently of albuminuria and renal function decline: A cross-sectional study.
    Petrica L; Vlad M; Vlad A; Gluhovschi G; Gadalean F; Dumitrascu V; Popescu R; Gluhovschi C; Matusz P; Velciov S; Bob F; Ursoniu S; Vlad D
    J Diabetes Complications; 2017 Sep; 31(9):1444-1450. PubMed ID: 28161386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary podocyte-associated mRNA levels correlate with proximal tubule dysfunction in early diabetic nephropathy of type 2 diabetes mellitus.
    Petrica L; Ursoniu S; Gadalean F; Vlad A; Gluhovschi G; Dumitrascu V; Vlad D; Gluhovschi C; Velciov S; Bob F; Matusz P; Milas O; Secara A; Simulescu A; Popescu R
    Diabetol Metab Syndr; 2017; 9():31. PubMed ID: 28484521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin ameliorates podocyte injury in patients with type 2 diabetes complicated with dyslipidemia.
    Takemoto M; Ishikawa T; Onishi S; Okabe E; Ishibashi R; He P; Kobayashi K; Fujimoto M; Kawamura H; Yokote K
    Diabetes Res Clin Pract; 2013 Apr; 100(1):e26-9. PubMed ID: 23312613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long noncoding RNAs may impact podocytes and proximal tubule function through modulating miRNAs expression in Early Diabetic Kidney Disease of Type 2 Diabetes Mellitus patients.
    Petrica L; Hogea E; Gadalean F; Vlad A; Vlad M; Dumitrascu V; Velciov S; Gluhovschi C; Bob F; Ursoniu S; Jianu DC; Matusz P; Pusztai AM; Motoc A; Cretu OM; Radu D; Milas O; Golea-Secara A; Simulescu A; Mogos-Stefan M; Patruica M; Balint L; Ienciu S; Vlad D; Popescu R
    Int J Med Sci; 2021; 18(10):2093-2101. PubMed ID: 33859515
    [No Abstract]   [Full Text] [Related]  

  • 7. Deregulated profiles of urinary microRNAs may explain podocyte injury and proximal tubule dysfunction in normoalbuminuric patients with type 2 diabetes mellitus.
    Milas O; Gadalean F; Vlad A; Dumitrascu V; Gluhovschi C; Gluhovschi G; Velciov S; Popescu R; Bob F; Matusz P; Pusztai AM; Cretu OM; Secara A; Simulescu A; Ursoniu S; Vlad D; Petrica L
    J Investig Med; 2018 Apr; 66(4):747-754. PubMed ID: 29279420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pro-inflammatory cytokines are associated with podocyte damage and proximal tubular dysfunction in the early stage of diabetic kidney disease in type 2 diabetes mellitus patients.
    Milas O; Gadalean F; Vlad A; Dumitrascu V; Velciov S; Gluhovschi C; Bob F; Popescu R; Ursoniu S; Jianu DC; Matusz P; Pusztai AM; Secara A; Simulescu A; Stefan M; Patruica M; Petrica F; Vlad D; Petrica L
    J Diabetes Complications; 2020 Feb; 34(2):107479. PubMed ID: 31806428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proximal tubule dysfunction is dissociated from endothelial dysfunction in normoalbuminuric patients with type 2 diabetes mellitus: a cross-sectional study.
    Petrica L; Petrica M; Vlad A; Jianu DC; Gluhovschi G; Ianculescu C; Firescu C; Dumitrascu V; Giju S; Gluhovschi C; Bob F; Gadalean F; Ursoniu S; Velciov S; Bozdog G; Milas O
    Nephron Clin Pract; 2011; 118(2):c155-64. PubMed ID: 21150223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial.
    Petrica L; Petrica M; Vlad A; Dragos Jianu C; Gluhovschi G; Ianculescu C; Dumitrascu V; Giju S; Gluhovschi C; Bob F; Ursoniu S; Gadalean F; Velciov S; Bozdog G; Marian R
    Wien Klin Wochenschr; 2009; 121(23-24):765-75. PubMed ID: 20047115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycated peptides are associated with proximal tubule dysfunction in type 2 diabetes mellitus.
    Petrica L; Vlad A; Gluhovschi G; Zamfir A; Popescu C; Gadalean F; Dumitrascu V; Vlad D; Popescu R; Velciov S; Gluhovschi C; Bob F; Milas O; Ursoniu S
    Int J Clin Exp Med; 2015; 8(2):2516-25. PubMed ID: 25932197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: a cross-sectional study.
    Petrica L; Vlad A; Gluhovschi G; Gadalean F; Dumitrascu V; Vlad D; Popescu R; Velciov S; Gluhovschi C; Bob F; Ursoniu S; Petrica M; Jianu DC
    J Diabetes Complications; 2015 Mar; 29(2):230-7. PubMed ID: 25511877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man.
    Coughlan MT; Patel SK; Jerums G; Penfold SA; Nguyen TV; Sourris KC; Panagiotopoulos S; Srivastava PM; Cooper ME; Burrell LM; Macisaac RJ; Forbes JM
    Am J Nephrol; 2011; 34(4):347-55. PubMed ID: 21876347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eucalyptol Inhibits Advanced Glycation End Products-Induced Disruption of Podocyte Slit Junctions by Suppressing Rage-Erk-C-Myc Signaling Pathway.
    Kim DY; Kang MK; Lee EJ; Kim YH; Oh H; Kang YH
    Mol Nutr Food Res; 2018 Oct; 62(19):e1800302. PubMed ID: 29987888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
    Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ezrin contributes to impaired podocyte migration and adhesion caused by advanced glycation end products.
    McRobert EA; Bach LA
    Nephrology (Carlton); 2016 Jan; 21(1):13-20. PubMed ID: 26032400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia.
    Werida R; Khairat I; Khedr NF
    Biomed Pharmacother; 2021 Mar; 135():111179. PubMed ID: 33401219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy.
    Weil EJ; Lemley KV; Mason CC; Yee B; Jones LI; Blouch K; Lovato T; Richardson M; Myers BD; Nelson RG
    Kidney Int; 2012 Nov; 82(9):1010-7. PubMed ID: 22718189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
    Jung E; Kim J; Ho Kim S; Kim S; Cho MH
    Eur J Pharmacol; 2015 Aug; 761():116-24. PubMed ID: 25977232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary podocyte mRNAs precede microalbuminuria as a progression risk marker in human type 2 diabetic nephropathy.
    Fukuda A; Minakawa A; Kikuchi M; Sato Y; Nagatomo M; Nakamura S; Mizoguchi T; Fukunaga N; Shibata H; Naik AS; Wiggins RC; Fujimoto S
    Sci Rep; 2020 Oct; 10(1):18209. PubMed ID: 33097787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.